Liberal phosphate target

PreclinicalSmall molecule

TThe University of Queensland

Liberal phosphate target is one of 49 small molecule programs targeting Kidney Disease. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Kidney DiseaseActive, not recruiting

Kidney Failure, ChronicRecruiting

Kidney DiseasePreclinical

Active, not recruiting

Kidney Failure, ChronicPreclinical

Recruiting

Competition

Competitive Landscape

105 competitors in Kidney Disease

#DrugCompanyPhaseTrials

Norvir

Tafinlar

Xtandi

Medrol

Afinitor

Maxipime

Kisqali

Nexavar

Zyloprim

Myrbetriq

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

PreclinicalRecruiting

Kidney Failure, Chronic

NCT03573089

Clinical

Trials by Indication[1]

Kidney Failure, Chronic1 trial

An Investigator-initiated, International, Multi-centre, Prospective, Randomized, Open-label, Parallel-group, Superiority, and Pragmatic Large Simple Trial (LST) to Determine Whether the Currently Recommended Strategy of Intensive Reduction of Serum Phosphate Concentration Towards the Normal Level Results in Significant Patient-centred Benefits in End-stage Kidney Disease (ESKD) Patients Receiving Dialysis.

Recruiting·TThe University of Queensland·Preclinical·NCT03573089·3,600 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Liberal phosphate target. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Liberal phosphate target compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Liberal phosphate target. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The University of Queensland company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: TThe University of Queensland

Liberal phosphate target

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Kidney Failure, Chronic1 trial

References

Drug Info

Quick Facts

Related News